The European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorization for Juluca for the treatment of
HIV infection in adults who are virologically suppressed on a stable
antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.
